At a glance
ClinicalIndex Comparison RecordPhase 2Unknown· 15 target
Drug / intervention
SHR1701drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Director of Shandong Cancer Hospital and Institute
In Brief
A Phase 2 clinical trial evaluating SHR1701 for Non-Small-Cell Lung Cancer. Targeting 15 participants.
Detailed Summary
This study is a single center, single arm, open study design. The main purpose of this study is to evaluate the tolerance and efficacy of SHR1701 with synchronous radiotherapy in patients with metastatic non-small cell lung cancer who have failed after systematic treatment. Large fraction radiotherapy is given to all lesions as much as possible, and low-dose radiotherapy is given to the lesions that cannot be tolerated or have no obvious benefit.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-Small-Cell Lung Cancer
Countries--
Collaborators--
Timeline
Phase 2UnknownOverdue
202120222023202420252026
Enrollment StartSep 2020
First PostedSep 2020
Primary CompletionSep 2022
Study CompletionDec 2022
TodayJul 2026
First PostedSep 23, 2020
Enrollment StartSep 1, 2020
Primary CompletionSep 1, 2022
Study CompletionDec 1, 2022
TodayJul 1, 2026
Enrollment to primary: 2 yearsPosted 5.8 years ago
Interventions
SHR1701drug
PD-L1 / TGF-β RII double antibody